| Dr Eddy Severe Bruno, MD | |
|
920 W Market St, Suite 310, Lima, OH 45805-2773 | |
| (419) 225-8808 | |
| (419) 222-7220 |
| Full Name | Dr Eddy Severe Bruno |
|---|---|
| Gender | Male |
| Speciality | Psychiatry |
| Experience | 32 Years |
| Location | 920 W Market St, Lima, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1427080530 | NPI | - | NPPES |
| 2582709 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 35082630 (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mercy Health-st Rita's Medical Center | Lima, OH | Hospital |
| Van Wert County Hospital | Van wert, OH | Hospital |
| Lima Memorial Health System | Lima, OH | Hospital |
| Entity Name | Westwood Behavioral Health Center, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639108764 PECOS PAC ID: 6901794015 Enrollment ID: O20040310000050 |
News Archive
The body's natural inflammatory response is an essential reaction to injury and infection. When acute inflammation escalates out of control, such as in sepsis, it causes nearly 10% of deaths in the U.S. and more than $17 billion in healthcare costs each year. A group of researchers have developed a groundbreaking biohybrid device that can control acute inflammation to prevent sepsis and other related life-threatening complications, as described in an article in the inaugural issue of Disruptive Science and Technology.
Ashoka and Boehringer Ingelheim announced today that they will launch a three-year global initiative to improve health in communities around the world. The "Making More Health" initiative will promote healthy individuals, families and communities by identifying and supporting the most promising solutions to challenging health problems.
Tenet Healthcare Corporation today reported adjusted EBITDA of $281 million for the fourth quarter ended December 31, 2010, an increase of $63 million, or 28.9 percent, compared to $218 million for the fourth quarter of 2009. Net income attributable to common shareholders for the fourth quarter of 2010 was $74 million, or $0.14 per diluted share, compared to $21 million, or $0.04 per diluted share, for the fourth quarter of 2009.
Eli Lilly and Company today announced that the U.S. District Court for the Southern District of Indiana has upheld the validity of the company's compound patent on Gemzar® (gemcitabine HCl for injection). This decision maintains Lilly's U.S. exclusivity for Gemzar through November 15, 2010.
› Verified 4 days ago
| Entity Name | Eddys Bruno Md Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952334609 PECOS PAC ID: 9436166469 Enrollment ID: O20060315000444 |
News Archive
The body's natural inflammatory response is an essential reaction to injury and infection. When acute inflammation escalates out of control, such as in sepsis, it causes nearly 10% of deaths in the U.S. and more than $17 billion in healthcare costs each year. A group of researchers have developed a groundbreaking biohybrid device that can control acute inflammation to prevent sepsis and other related life-threatening complications, as described in an article in the inaugural issue of Disruptive Science and Technology.
Ashoka and Boehringer Ingelheim announced today that they will launch a three-year global initiative to improve health in communities around the world. The "Making More Health" initiative will promote healthy individuals, families and communities by identifying and supporting the most promising solutions to challenging health problems.
Tenet Healthcare Corporation today reported adjusted EBITDA of $281 million for the fourth quarter ended December 31, 2010, an increase of $63 million, or 28.9 percent, compared to $218 million for the fourth quarter of 2009. Net income attributable to common shareholders for the fourth quarter of 2010 was $74 million, or $0.14 per diluted share, compared to $21 million, or $0.04 per diluted share, for the fourth quarter of 2009.
Eli Lilly and Company today announced that the U.S. District Court for the Southern District of Indiana has upheld the validity of the company's compound patent on Gemzar® (gemcitabine HCl for injection). This decision maintains Lilly's U.S. exclusivity for Gemzar through November 15, 2010.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Eddy Severe Bruno, MD Po Box 217, Lima, OH 45802-0217 Ph: (419) 225-8808 | Dr Eddy Severe Bruno, MD 920 W Market St, Suite 310, Lima, OH 45805-2773 Ph: (419) 225-8808 |
News Archive
The body's natural inflammatory response is an essential reaction to injury and infection. When acute inflammation escalates out of control, such as in sepsis, it causes nearly 10% of deaths in the U.S. and more than $17 billion in healthcare costs each year. A group of researchers have developed a groundbreaking biohybrid device that can control acute inflammation to prevent sepsis and other related life-threatening complications, as described in an article in the inaugural issue of Disruptive Science and Technology.
Ashoka and Boehringer Ingelheim announced today that they will launch a three-year global initiative to improve health in communities around the world. The "Making More Health" initiative will promote healthy individuals, families and communities by identifying and supporting the most promising solutions to challenging health problems.
Tenet Healthcare Corporation today reported adjusted EBITDA of $281 million for the fourth quarter ended December 31, 2010, an increase of $63 million, or 28.9 percent, compared to $218 million for the fourth quarter of 2009. Net income attributable to common shareholders for the fourth quarter of 2010 was $74 million, or $0.14 per diluted share, compared to $21 million, or $0.04 per diluted share, for the fourth quarter of 2009.
Eli Lilly and Company today announced that the U.S. District Court for the Southern District of Indiana has upheld the validity of the company's compound patent on Gemzar® (gemcitabine HCl for injection). This decision maintains Lilly's U.S. exclusivity for Gemzar through November 15, 2010.
› Verified 4 days ago
Ali S Almudallal, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 770 W High St, Suite 160, Lima, OH 45801 Phone: 419-996-5224 Fax: 419-996-5276 | |
David Kashan, DO Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 770 W High St Ste 300, Lima, OH 45801 Phone: 419-996-5033 Fax: 419-996-5266 | |
Dr. Richard A Nockowitz, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 1800 Allentown Rd, Lima, OH 45805 Phone: 419-229-0415 Fax: 419-229-0419 | |
Marietta J Medel, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1005 Bellefontaine Ave Ste 350, Lima, OH 45804 Phone: 419-998-8200 Fax: 419-998-8203 | |
Josef Froehlich, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 770 W High St, Suite 300, Lima, OH 45801 Phone: 419-996-5033 Fax: 419-996-5266 | |
Patricia Bauza, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1001 Bellefontaine Ave, Lima, OH 45804 Phone: 419-228-3335 |